Gene-Therapy Update: Mixed Results Don’t Dim Hopes – Barron’s
SMA News Today |
Gene–Therapy Update: Mixed Results Don't Dim Hopes
Barron’s Three companies developing replacement gene–therapy treatments provided updates last week on clinical trials. Investors were happy with the news at Audentes Therapeutics (ticker: BOLD), and disappointed with what they heard from Avexis (AVXS) and … FDA Lets AveXis Know the Information It Needs to Approve AVXS-101 for SMA Type 1 REGENXBIO and AveXis Announce Expansion of Relationship through Amended License Agreement for the … |
